Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of TAK-195 (sIPV) in Infants, Toddlers, and Adults
NCT03092791Phase 2Terminated
- Sponsor
- Takeda
- Start
- Jun 2017
- Primary completion
- Apr 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Sabin-Based Inactivated Poliomyelitis Vaccine in poliomyelitis, sponsored by Takeda. Started Jun 2017; status: terminated.
02
Drugs
Sabin-Based Inactivated Poliomyelitis Vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT03092791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03092791.